drugset
drugset / Trial / NCT05368831

Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects

NCT05368831 ↗

Phase 1 Completed 24 enrolled NorthSea Therapeutics B.V.
NaSingle-groupOpen-labelDiagnostic

Summary

Phase 1, open label study to evaluate the effects of NST-1024 on the pharmacokinetics (PK) of caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam (and 1-hydroxymidazolam) in healthy male and female subjects.

Timeline

Start
2022-07-19
Primary completion
2022-09-07
Completion
2022-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NST-1024 Unknown 200 mg Oral

Indications

No indication recorded.